Wellington Management Group LLP Lowers Stock Holdings in Twist Bioscience Corporation $TWST

Wellington Management Group LLP cut its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 23.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 568,347 shares of the company’s stock after selling 170,282 shares during the quarter. Wellington Management Group LLP owned approximately 0.91% of Twist Bioscience worth $58,472,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Empowered Funds LLC purchased a new stake in shares of Twist Bioscience in the second quarter valued at approximately $214,000. Corient Private Wealth LP bought a new stake in Twist Bioscience during the 2nd quarter valued at $2,226,000. Bank of America Corp DE purchased a new stake in shares of Twist Bioscience in the 2nd quarter worth $94,922,000. Odyssean LLC purchased a new stake in shares of Twist Bioscience in the 2nd quarter worth $2,699,000. Finally, Man Group plc bought a new position in shares of Twist Bioscience during the 2nd quarter worth $5,997,000.

Analyst Ratings Changes

TWST has been the subject of several recent research reports. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Barclays lifted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a research note on Monday, June 15th. Finally, Leerink Partners set a $110.00 target price on Twist Bioscience in a report on Thursday, July 16th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.30.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 41,570 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $151.98, for a total value of $6,317,808.60. Following the transaction, the chief executive officer directly owned 770,729 shares of the company’s stock, valued at $117,135,393.42. This represents a 5.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the transaction, the insider owned 105,141 shares of the company’s stock, valued at $9,436,404.75. This trade represents a 11.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 193,099 shares of company stock valued at $24,026,581. 3.08% of the stock is currently owned by corporate insiders.

Twist Bioscience Stock Down 1.7%

Twist Bioscience stock opened at $128.71 on Friday. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $155.44. The business has a fifty day moving average price of $110.41 and a 200-day moving average price of $76.37. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a market capitalization of $8.07 billion, a price-to-earnings ratio of -57.98 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.Twist Bioscience’s revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 EPS. Equities research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.